No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ALZN Alzamend Neuro
- 0.6200
- -0.0098-1.56%
Close May 22 16:00 ET
4.27MMarket Cap-340P/E (TTM)
0.6800High0.6000Low56.93KVolume0.6590Open0.6298Pre Close36.09KTurnover1.18%Turnover RatioLossP/E (Static)6.88MShares11.910052wk High-1.00P/B3.00MFloat Cap0.438852wk Low--Dividend TTM4.84MShs Float503.2500Historical High--Div YieldTTM12.70%Amplitude0.4388Historical Low0.6330Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Nasdaq Hearings Panel Granted Alzamend's Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disor
Express News | Alzamend Neuro Announces Favorable Decision From Nasdaq Hearings Panel
Alzamend Neuro Unveils Updated Investor Presentation Outlook
Express News | Alzamend Neuro Inc: Expects to Use Proceeds to Further Its Clinical Trials and Working Capital Purposes
Express News | Alzamend Neuro Inc: Investor Had Agreed to Purchase up to $25 Mln of Preferred Shares
Express News | Alzamend Neuro Announces Initial Closing of Private Placement
Comments
Alzamend Neuro's Strategic Move: A $25 Million Leap Forward Through Private Placement.
Alzamend Neuro Inc. has laid out plans to secure up to $25 million through a private placement of preferred shares, a strategic maneuver aimed at bolstering its financial stature and accelerating its mission against Alzheimer's disease. This move marks a pivotal moment for the biotechnology firm, emphasizing its relentless...
Alzamend Neuro Inc. has laid out plans to secure up to $25 million through a private placement of preferred shares, a strategic maneuver aimed at bolstering its financial stature and accelerating its mission against Alzheimer's disease. This move marks a pivotal moment for the biotechnology firm, emphasizing its relentless...
$Alzamend Neuro(ALZN.US$ EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Announces Agreement For Registered Direct Offering And Concurrent Private Placement For An Aggregate Of Up To $25M
6
$Alzamend Neuro(ALZN.US$ Reuters· just
Alzamend Neuro Announces Termination of at-the-Market Equity Offering Program
Alzamend Neuro Announces Termination of at-the-Market Equity Offering Program
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg